HomeCompareESALY vs CL

ESALY vs CL: Dividend Comparison 2026

ESALY yields 31.26% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESALY wins by $257.9K in total portfolio value
10 years
ESALY
ESALY
● Live price
31.26%
Share price
$61.51
Annual div
$19.23
5Y div CAGR
7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$298.7K
Annual income
$71,135.45
Full ESALY calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — ESALY vs CL

📍 ESALY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALYCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALY + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALY pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALY
Annual income on $10K today (after 15% tax)
$2,657.23/yr
After 10yr DRIP, annual income (after tax)
$60,465.13/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, ESALY beats the other by $55,873.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALY + CL for your $10,000?

ESALY: 50%CL: 50%
100% CL50/50100% ESALY
Portfolio after 10yr
$169.7K
Annual income
$38,268.70/yr
Blended yield
22.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ESALY
No analyst data
Altman Z
5.1
Piotroski
4/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALY buys
0
CL buys
0
No recent congressional trades found for ESALY or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALYCL
Forward yield31.26%2.43%
Annual dividend / share$19.23$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR7%28.6%
Portfolio after 10y$298.7K$40.8K
Annual income after 10y$71,135.45$5,401.96
Total dividends collected$238.7K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ESALY vs CL ($10,000, DRIP)

YearESALY PortfolioESALY Income/yrCL PortfolioCL Income/yrGap
1← crossover$14,045$3,344.99$11,012$312.01+$3.0KESALY
2$19,726$4,698.03$12,196$412.95+$7.5KESALY
3$27,705$6,598.37$13,599$549.66+$14.1KESALY
4$38,912$9,267.41$15,288$736.64+$23.6KESALY
5$54,652$13,016.06$17,353$995.28+$37.3KESALY
6$76,759$18,281.04$19,926$1,357.80+$56.8KESALY
7$107,808$25,675.69$23,194$1,873.82+$84.6KESALY
8$151,416$36,061.47$27,439$2,621.52+$124.0KESALY
9$212,663$50,648.29$33,088$3,727.38+$179.6KESALY
10$298,685$71,135.45$40,806$5,401.96+$257.9KESALY

ESALY vs CL: Complete Analysis 2026

ESALYStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALY Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ESALY vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALY vs SCHDESALY vs JEPIESALY vs OESALY vs KOESALY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.